Diagnosing Disorders of Hypopigmentation and Depigmentation in Patients with Skin of Color
Ceresnie MS, Gonzalez S, and Hamzavi IH. Diagnosing Disorders of Hypopigmentation and Depigmentation in Patients with Skin of Color. Dermatol Clin 2023.
Skin hypopigmentation and depigmentation disorders are a top concern for patients with skin of color seeking care from a dermatologist. The visual contrast between involved and uninvolved skin in these disorders makes them particularly burdensome for patients with skin of color. These disorders may have a wide differential of diagnosis, as patients with skin of color may present differently or more frequently than White patients for certain conditions. Clues from a comprehensive history and physical examination with standard lighting and a Wood’s light are essential for clinching the diagnosis, although a biopsy may be warranted in special cases.
ePub ahead of print
M.S. Ceresnie is a subinvestigator for Avita Medical, Incyte Corporation, Clinuvel Pharmaceuticals, and The Immune Tolerance Network. I.H. Hamzavi helped develop the vitiligo area scoring index but does not have a proprietary interest in the score and has served as an advisory board member for AbbVie; a consultant for Incyte Corporation, Pfizer, and UCB; a principal investigator for AbbVie, Bayer, Clinuvel Pharmaceuticals, Estée Lauder, Ferndale Laboratories, Galderma Laboratories LP, GE Healthcare, Incyte Corporation, Janssen, Janssen Biotech, Johnson & Johnson, Lenicura, LEO Pharma, Pfizer, and Unigen; a subinvestigator for Amgen, Bristol Myers Squibb, Foamix Pharmaceuticals, and Janssen; past-president of the Hidradenitis Suppurativa Foundation; and co-chair of the Global Vitiligo Foundation. The authors have no other relevant disclosures.